Connect with us


AXIM Biotechnologies Inc. (OTCMKTS: AXIM) Offers Updates In SPX-1009 Compound And COVID-19 Neutralizing Antibodies Test



AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has finalized pre-clinical drug studies on the patent waiting for compound SPX-1009, showing malignant metastatic melanoma cells suppression. Dr. Douglas Lake’s lab at Arizona State University completed the independent research. 

AXIM finalizes SPX-1009 studies 

John W. Huemoeller II, AXIM Biotechnologies CEO, said, “We are extremely excited with the results of the in vitro testing. This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.”

The study screened SPX-1009 in a cell-free enzymatic assay for the ability to suppress Quiescin Sulfhydryl oxidase I (QSOXI). QSOXI is a tumor-derived enzyme vital in cancer growth, metastasis, and invasion, which was tested for the ability to suppress invasion and growth of established A375 melanoma cell line and the low-passage patient der4eived melanoma. The study employed 3D tumor spheroid assays and 2D invasion assays to ascertain the compounds’ impact on tumor suppression. 

The company’s next step is initiating animal studies to show SPX-1009’s ability to suppress metastasis and tumor growth in a murine melanoma model. In addition, the IP related to the SPX-1009 tech is subject to various patent-pending applications.

AXIM files for emergency approval for ImmunoPass

AXIM Biotechnologies recently announced that Empowered Diagnostics, its manufacturing partner, had filed an emergency approval for ImmunoPass. ImmunoPass is the company’s rapid test that measures COVID-19 neutralizing antibody levels to establish the presence of neutralizing antibodies in whole blood. 

Huemoeller II said, “The COVID-19 pandemic itself is evidence that the world is interconnected. Because of that, it’s crucial that countries work together to resolve this global issue and have a consistent level of care in order to achieve relative normalcy as quickly as possible. In addition, ImmunoPass is incredibly easy to use and delivers accurate results in a matter of minutes, making it an ideal device for global use.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.